Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Sep;28(3):305–314. doi: 10.1111/j.1365-2125.1989.tb05431.x

Population pharmacokinetics of tobramycin.

L Aarons 1, S Vozeh 1, M Wenk 1, P Weiss 1, F Follath 1
PMCID: PMC1379949  PMID: 2789924

Abstract

1. Population pharmacokinetic parameters of tobramycin were determined in a heterogenous group of 97 patients using serum samples drawn for the routine monitoring of tobramycin concentrations, following multiple dosing regimens. 2. To describe the accumulation kinetics of tobramycin a two-compartment pharmacokinetic model was required. The best fit to the data was obtained when drug clearance (1 h-1) was related linearly to creatinine clearance (proportionality constant: 0.059 +/- 0.002 x CLcr (ml min-1)) and initial volume of distribution (1) was related linearly to body weight (proportionality constant: 0.327 +/- 0.014 x body weight (kg)). The intersubject variability in these two parameters was 32% and 3%, respectively, whilst the residual or intrasubject variability amounted to 21% of the tobramycin concentration. The terminal half-life of tobramycin, 26.6 +/- 9.4 h, was appreciably shorter than previously reported. 3. The population pharmacokinetic model was validated against data obtained from 34 independent patients and the predicted and observed concentrations were found to be in good agreement. The population pharmacokinetic model was used to design a priori dosing recommendations for tobramycin.

Full text

PDF
305

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barza M., Lauermann M. Why monitor serum levels of gentamicin? Clin Pharmacokinet. 1978 May-Jun;3(3):202–215. doi: 10.2165/00003088-197803030-00002. [DOI] [PubMed] [Google Scholar]
  2. Bauer L. A., Edwards W. A., Dellinger E. P., Simonowitz D. A. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983;24(5):643–647. doi: 10.1007/BF00542215. [DOI] [PubMed] [Google Scholar]
  3. Burton M. E., Brater D. C., Chen P. S., Day R. B., Huber P. J., Vasko M. R. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther. 1985 Mar;37(3):349–357. doi: 10.1038/clpt.1985.51. [DOI] [PubMed] [Google Scholar]
  4. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  5. Evans W. E., Taylor R. H., Feldman S., Crom W. R., Rivera G., Yee G. C. A model for dosing gentamicin in children and adolescents that adjusts for tissue accumulation with continuous dosing. Clin Pharmacokinet. 1980 May-Jun;5(3):295–306. doi: 10.2165/00003088-198005030-00007. [DOI] [PubMed] [Google Scholar]
  6. Follath F., Wenk M., Vozeh S. Plasma concentration monitoring of aminoglycosides. J Antimicrob Chemother. 1981 Jul;8 (Suppl A):37–43. doi: 10.1093/jac/8.suppl_a.37. [DOI] [PubMed] [Google Scholar]
  7. Francke E. L., Srinivasan S., Labthavikul P., Neu H. C. Rapid, reproducible enzyme immunoassay for tobramycin. J Clin Microbiol. 1981 Jan;13(1):93–96. doi: 10.1128/jcm.13.1.93-96.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gerber A. U., Brugger H. P., Feller C., Stritzko T., Stalder B. Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics. J Infect Dis. 1986 Jan;153(1):90–97. doi: 10.1093/infdis/153.1.90. [DOI] [PubMed] [Google Scholar]
  9. Kahlmeter G., Jonsson S., Kamme C. Longstanding post-therapeutic gentamicin serum and urine concentrations in patients with unimpaired renal function. A pharmacokinetic evaluation. J Antimicrob Chemother. 1978 Mar;4(2):143–152. doi: 10.1093/jac/4.2.143. [DOI] [PubMed] [Google Scholar]
  10. King C. H., Creger R. J., Ellner J. J. Pharmacokinetics of tobramycin and gentamicin in abusers of intravenous drugs. Antimicrob Agents Chemother. 1985 Mar;27(3):285–290. doi: 10.1128/aac.27.3.285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Laskin O. L., Longstreth J. A., Smith C. R., Lietman P. S. Netilmicin and gentamicin multidose kinetics in normal subjects. Clin Pharmacol Ther. 1983 Nov;34(5):644–650. doi: 10.1038/clpt.1983.227. [DOI] [PubMed] [Google Scholar]
  12. Moore R. D., Smith C. R., Lietman P. S. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984 Oct;77(4):657–662. doi: 10.1016/0002-9343(84)90358-9. [DOI] [PubMed] [Google Scholar]
  13. Moore R. D., Smith C. R., Lietman P. S. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984 Mar;149(3):443–448. doi: 10.1093/infdis/149.3.443. [DOI] [PubMed] [Google Scholar]
  14. Powell S. H., Thompson W. L., Luthe M. A., Stern R. C., Grossniklaus D. A., Bloxham D. D., Groden D. L., Jacobs M. R., DiScenna A. O., Cash H. A. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis. 1983 May;147(5):918–932. doi: 10.1093/infdis/147.5.918. [DOI] [PubMed] [Google Scholar]
  15. Schentag J. J., Lasezkay G., Cumbo T. J., Plaut M. E., Jusko W. J. Accumulation pharmacokinetics of tobramycin. Antimicrob Agents Chemother. 1978 Apr;13(4):649–656. doi: 10.1128/aac.13.4.649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Schwartz S. N., Pazin G. J., Lyon J. A., Ho M., Pasculle A. W. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis. 1978 Oct;138(4):499–505. doi: 10.1093/infdis/138.4.499. [DOI] [PubMed] [Google Scholar]
  17. Vozeh S., Spring P., Wenk M., Follath F. Changes in the apparent half life of gentamicin and tobramycin without detectable changes in creatinine clearance. Br J Clin Pharmacol. 1979 Jun;7(6):629–631. doi: 10.1111/j.1365-2125.1979.tb04656.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wenk M., Vozeh S., Follath F. Serum level monitoring of antibacterial drugs. A review. Clin Pharmacokinet. 1984 Nov-Dec;9(6):475–492. doi: 10.2165/00003088-198409060-00001. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES